17-(Cyclobutylmethyl)morphinan-3,14-diyl-[S-(R*,R*)]-2,3-dihydroxysuccinat

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H361：Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen.

• Sicherheit

  P201：Vor Gebrauch besondere Anweisungen einholen.

  P308+P313：BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

Butorphanol tartrate Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R22:Gesundheitsschädlich beim Verschlucken.
  R63:Kann das Kind im Mutterleib möglicherweise schädigen.

• S-Sätze Betriebsanweisung:

  S22:Staub nicht einatmen.
  S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
  S36/37/39:Bei der Arbeit geeignete Schutzkleidung,Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.

• Beschreibung

  Butorphanol (tartrate) (Item No. 23812) is an analytical reference material categorized as an opioid. Butorphanol is regulated as a Schedule IV compound in the United States. This product is intended for research and forensic applications.

• Verwenden

  Analgesic; antitussive.

• Definition

  ChEBI: The (S,S)-tartaric acid salt of butorphanol. It is used for relief or moderate to severe pain.

• Trademarks

  Stadol (Bristol-Myers Squibb).

• Biochem/physiol Actions

  κ/μ opioid receptor agonist.

• Mechanism of action

  Butorphanol is a strong agonist at κ opioid receptors, and through this interaction, it is five times more potent than morphine as an analgesic. The κagonists have a lower ceiling analgesic effect than full μ agonists; thus, they are not as effective in treating severe pain. Butorphanol is an antagonist at μ opioid receptors with approximately one-sixth the potency of naloxone. If given to a person addicted to a μ agonist, butorphanol will induce an immediate onset of abstinence syndrome.

• Nebenwirkungen

  Butorphanol has a different spectrum of side effects than μ opioid analgesics. Respiratory depression occurs. There is a lower ceiling on this effect, however, and it is not generally lethal, as is the case with high doses of μ agonists. Major side effects after normal analgesic doses are sedation, nausea, and sweating, as well as dysphoric (hallucinogenic) effects at higher doses. Butorphanol causes an increase in pulmonary arterial pressure and pulmonary vascular resistance. There is an overall increased workload on the heart, and it should not be used in patients with congestive heart failure or to treat pain from acute myocardial infarction. Butorphanol has low abuse potential and is not a scheduled drug.

• Veterinary Drugs and Treatments

  Approved indication for dogs is “. . . for the relief of chronic nonproductive cough associated with tracheobronchitis, tracheitis, tonsillitis, laryngitis and pharyngitis originating from inflammatory conditions of the upper respiratory tract” (Package Insert; Torbutrol?—Fort Dodge). It is also used in practice in both dogs and cats as a preanesthetic medication, analgesic, and as an antiemetic prior to cisplatin treatment (although not very effective in cats for this indication). Compared with other opiate analgesics, butorphanol is not very useful in small animals (particularly dogs) for treating pain and has to be dosed frequently.
  The approved indication for horses is “. . . for the relief of pain associated with colic in adult horses and yearlings” (Package Insert; Torbugesic?—Fort Dodge). It has also been used clinically as an analgesic in cattle.

17-(Cyclobutylmethyl)morphinan-3,14-diyl-[S-(R*,R*)]-2,3-dihydroxysuccinat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(68)Suppliers

58786-99-5, Butorphanol tartrate Verwandte Suche: